查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1951328

臨床前CRO市場－全球產業規模、佔有率、趨勢、機會及預測（依服務、模式類型、最終用途產業、地區及競爭格局分類，2021-2031年）

Preclinical CRO Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Service, By Model Type (Patient Derived Organoid, Model, Patient derived xenograft model), By End-Use Industry, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 185 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球臨床前 CRO 市場預計將從 2025 年的 66.7 億美元成長到 2031 年的 111.3 億美元，複合年成長率為 8.91%。

該領域包括提供關鍵早期研究服務的第三方供應商，例如毒性評估、生物分析和藥物代謝評價，以檢驗人體臨床試驗前候選療法的安全性和有效性。主要成長要素是藥物發現過程日益複雜，以及生物製藥公司在最大限度降低財務風險的同時加快研發進程的需求不斷成長。因此，申辦方經常將這些關鍵活動外包，以利用內部維護成本過高的專業知識和基礎設施。

市場概覽
預測期 2027-2031
市場規模：2025年 66.7億美元
市場規模：2031年 111.3億美元
複合年成長率：2026-2031年 8.91%
成長最快的細分市場 生物製藥公司
最大的市場 北美洲

儘管市場需求強勁，但由於國際機構實施的嚴格監管標準，市場面臨許多挑戰。這些標準通常需要耗費巨資執行合規通訊協定，並可能延誤計劃完成。然而，在推動外包業務發展的巨額創新投資的驅動下，該產業依然蓬勃發展。歐洲製藥工業協會聯合會 (EFPIA) 報告稱，歐洲製藥業預計將在 2024 年投入約 550 億歐元用於研發。持續的研發投入凸顯了受託研究機構(CRO) 在加速新型療法開發方面所扮演的重要角色。

市場促進因素

生物製藥公司為將固定內部成本轉化為可變外部支出，日益成長的策略性研發外包趨勢是全球臨床前CRO市場的主要驅動力。隨著藥物研發資本密集度的提高，主要企業正在縮減內部基礎設施，並與CRO建立一體化合作夥伴關係，以降低財務風險並獲得專業平台的使用權。服務供應商從大型企業客戶獲得的收入不斷成長，也印證了這項轉變。例如，藥明康德發布的《2024年年度報告》顯示，2024年全球前20大製藥公司的營收將達到166.4億元人民幣，年增24.1%。

同時，生物製藥和先進療法研發管線的快速成長正在改變市場需求。這些先進治療方法需要一些特殊的毒理學和生物分析技術，而這些技術很難在企業內部獲得。基因編輯和細胞療法的行業研究正在蓬勃發展，這需要專業的合約研究組織（CRO）提供先進的測試模型。美國基因與細胞治療學會（ASGCT）在其2024年6月年會總結中報告稱，摘要數量同比成長12%，約2000篇，這表明該領域正在擴張。這些持續的研究正在產生實際的市場成果。 2025年2月，Labcorp宣布其早期開發部門2024年第四季的營收成長了12.3%，凸顯了早期外包業務的強勁發展勢頭。

市場挑戰

嚴格的監管合規標準造成了複雜的商業環境，並直接阻礙了全球臨床前CRO市場的擴張。為了滿足FDA和EMA等機構制定的安全性和有效性標準，合約研究組織（CRO）必須維持高成本且嚴格的品質保證體系，並進行全面的毒理學研究。這些強制性的合規程序顯著增加了計劃完成所需的時間和資金，從而在開發平臺中造成了瓶頸。 CRO必須將大量資源投入監管文件和通訊協定檢驗中，而不是擴大生產能力，這減緩了候選藥物的研發速度，並限制了整體市場容量。

這些合規要求帶來的財務負擔進一步限制了市場成長，因為它們會耗盡原本可用於支援更多外包協議的研發預算。據美國藥品研究與製造商協會（PhRMA）稱，其成員公司將在2024年投入約152億美元用於非人體測試和非臨床試驗活動。這筆巨額支出凸顯了監管要求消耗了藥物研發資金的很大一部分。因此，申辦方在新專案申請方面面臨很高的准入門檻，導致研發管線整合加劇，以及外包給非臨床服務供應商的早期研究數量下降。

市場趨勢

人工智慧 (AI) 和機器學習在預測毒理學領域的應用正在改變這一領域，它將早期安全性評估從傳統的體內模型轉向先進的運算平台。服務供應商正在利用人工智慧驅動的演算法處理大量資料集，從而能夠及早發現毒性風險，並顯著降低藥物候選物在進行成本高昂的動物試驗之前被淘汰的比例。主要產業參與者投入大規模支持這項技術變革，他們希望檢驗能夠更準確預測不利事件的In Silico方法。正如 2025 年 10 月《全球創投》雜誌的一篇報導《賽諾菲創投注資 6.25 億美元聚焦人工智慧》所述，賽諾菲已向其企業創投基金注資 6.25 億美元，以擴大其對人工智慧驅動的藥物發現技術的關注，這標誌著其資本向預測工具的重大重新配置。

同時，透過策略性併購加速市場整合正在重塑競爭格局，各公司都在尋求建構整合化的端到端服務平台。為了解決專業服務分散的問題，市場參與企業正積極尋求併購，將濕實驗室能力與先進的計算技術相結合，以提供最佳化整個藥物研發生命週期的綜合解決方案。這一趨勢在「生物科技」公司與傳統合約研究模式的合作中尤為明顯，雙方攜手構建了能夠無縫銜接從靶點識別到先導藥物最適化的整合式藥物研發引擎。例如，Recursion Pharmaceuticals在其2025年2月發布的2024年度報告中宣布，已完成對Exscientia的收購，交易金額為6.301億美元。此次交易建立了一個垂直整合的平台，將生物工程和自動化化學相結合，服務於製藥業。

目錄

第1章概述

第2章調查方法

第3章執行摘要

第4章：客戶評價

第5章：全球臨床前CRO市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 按服務項目（生物分析/DMPK 測試、毒性測試、化合物管理、化學、安全藥理學、其他）
    • 依模型類型（病患來源類器官（PDO）模型、病患來源異種移植模型）
    • 依最終用戶產業分類（生物製藥公司、政府/學術機構、醫療設備公司）
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

6. 北美臨床前CRO市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國家分析
    • 美國
    • 加拿大
    • 墨西哥

7. 歐洲臨床前CRO市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國家分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

8. 亞太地區臨床前CRO市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國家分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

9. 中東和非洲臨床前CRO市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東和非洲：國家分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：南美臨床前CRO市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國家分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進要素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 最新進展

第13章 全球臨床前CRO市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的可能性
  • 供應商電力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • Eurofins Scientific SE
  • PRA Health Sciences, Inc.
  • Medpace, Inc.
  • Charles River Laboratories International, Inc.
  • PPD, Inc.
  • SGA SA
  • Intertek Group Plc
  • LABCORP Inc.
  • Crown Bioscience Inc

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 17068

The Global Preclinical CRO Market is projected to expand from USD 6.67 Billion in 2025 to USD 11.13 Billion by 2031, registering a CAGR of 8.91%. This sector encompasses third-party entities providing essential early-stage research services, including toxicology assessments, bioanalysis, and drug metabolism evaluations, designed to verify the safety and efficacy of therapeutic candidates prior to human trials. Key growth drivers include the increasing intricacy of drug discovery and the strategic need for biopharmaceutical firms to expedite development while minimizing financial exposure. Consequently, sponsors are frequently outsourcing these vital tasks to utilize specialized expertise and infrastructure that would be economically burdensome to sustain in-house.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 6.67 Billion
Market Size 2031USD 11.13 Billion
CAGR 2026-20318.91%
Fastest Growing SegmentBiopharmaceutical Companies
Largest MarketNorth America

Despite strong demand, the market encounters significant hurdles due to rigorous regulatory compliance standards mandated by international agencies, which often require expensive adherence protocols and can retard project completion. Nevertheless, the industry continues to thrive on substantial innovation investments that drive the outsourcing pipeline. As reported by the European Federation of Pharmaceutical Industries and Associations, the pharmaceutical sector allocated an estimated €55,000 million to R&D in Europe in 2024. This continuous capital investment in research and development highlights the critical function of contract research organizations in facilitating the progression of new therapeutics.

Market Driver

The growing trend of strategic R&D outsourcing by biopharmaceutical firms serves as a major driver for the Global Preclinical CRO Market, motivated by the need to transform fixed internal costs into variable external expenditures. With drug discovery becoming more capital-intensive, leading pharmaceutical companies are reducing internal infrastructure to form integrated alliances with contract research organizations, thereby mitigating financial risks and gaining access to specialized platforms. This shift is demonstrated by the rising revenues service providers are securing from large-cap clients; for example, WuXi AppTec's '2024 Annual Report' noted that revenue from the top 20 global pharmaceutical companies hit RMB 16.64 billion in 2024, marking a 24.1% year-over-year rise.

Concurrently, the surge in biologics and advanced therapy pipelines is altering demand, as these sophisticated modalities necessitate niche toxicology and bioanalysis skills often unavailable internally. The industry is seeing increased research into gene editing and cell-based therapies, which requires the advanced testing models offered by specialized CROs. The American Society of Gene & Cell Therapy reported in its June 2024 '2024 Annual Meeting' summary that the field's expansion was evidenced by nearly 2,000 abstract presentations, a 12% increase from the previous year. This ongoing research activity is yielding concrete market results, as Labcorp announced in February 2025 that its Early Development segment revenue increased by 12.3% in the fourth quarter of 2024, highlighting the strong momentum in early-stage outsourcing.

Market Challenge

Stringent regulatory compliance standards create a complex operational landscape that directly impedes the expansion of the Global Preclinical CRO Market. To satisfy safety and efficacy benchmarks established by bodies such as the FDA and EMA, contract research organizations are required to uphold costly, exacting quality assurance systems and perform comprehensive toxicology testing. These compulsory adherence steps substantially raise the time and capital needed for project completion, causing bottlenecks in the development pipeline. Because CROs must allocate significant resources to regulatory documentation and protocol validation instead of capacity growth, the speed at which they process new drug candidates slows, thereby restricting total market throughput.

The financial weight of these compliance mandates further limits market growth by depleting R&D budgets that might otherwise support additional outsourcing agreements. According to the Pharmaceutical Research and Manufacturers of America (PhRMA), member companies directed roughly $15.2 billion specifically toward pre-human and preclinical testing activities in 2024. This significant outlay underscores how regulatory requirements consume a large portion of discovery capital. As a result, sponsors encounter elevated entry barriers for new programs, frequently resulting in pipeline consolidation and a decrease in the number of early-stage studies assigned to preclinical service providers.

Market Trends

The incorporation of Artificial Intelligence and Machine Learning for Predictive Toxicology is transforming the sector by moving early-stage safety assessments from solely in vivo models to sophisticated computational platforms. Service providers are increasingly utilizing AI-driven algorithms to process massive datasets, enabling the early detection of toxicity risks and significantly lowering the attrition rate of drug candidates prior to expensive animal trials. This technological shift is supported by major capital investments from key industry players seeking to validate in silico methods capable of more accurately predicting adverse events. As noted by Global Venturing in October 2025, in the article 'Sanofi Ventures bets on AI with $625m cash influx', Sanofi injected $625 million into its corporate venture fund expressly to target and expand AI-driven drug discovery technologies, indicating a substantial reallocation of capital toward these predictive tools.

Simultaneously, the acceleration of market consolidation through strategic mergers and acquisitions is reshaping the competitive environment as entities aim to build integrated, end-to-end service platforms. To address the fragmentation of specialized services, market participants are actively engaging in M&A to merge wet-lab capacities with advanced computational technologies, delivering comprehensive solutions that optimize the drug development lifecycle. This trend is illustrated by the union of "TechBio" firms and conventional contract research models to form unified discovery engines that facilitate a smooth transition from target identification to lead optimization for partners. For instance, Recursion Pharmaceuticals stated in its February 2025 '2024 Annual Report' that it finalized the acquisition of Exscientia for $630.1 million, establishing a vertically integrated platform that combines biological engineering with automated chemistry to serve the pharmaceutical industry.

Key Market Players

  • Eurofins Scientific SE
  • PRA Health Sciences, Inc.
  • Medpace, Inc.
  • Charles River Laboratories International, Inc.
  • PPD, Inc.
  • SGA SA
  • Intertek Group Plc
  • LABCORP Inc.
  • Crown Bioscience Inc

Report Scope

In this report, the Global Preclinical CRO Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Preclinical CRO Market, By Service

  • Bioanalysis and DMPK studies
  • Toxicology Testing
  • Compound Management
  • Chemistry
  • Safety Pharmacology
  • Others

Preclinical CRO Market, By Model Type

  • Patient Derived Organoid (PDO) Model
  • Patient derived xenograft model

Preclinical CRO Market, By End-Use Industry

  • Biopharmaceutical Companies
  • Government and Academic Institutes
  • Medical Device Companies

Preclinical CRO Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Preclinical CRO Market.

Available Customizations:

Global Preclinical CRO Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Preclinical CRO Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Service (Bioanalysis and DMPK studies, Toxicology Testing, Compound Management, Chemistry, Safety Pharmacology, Others)
    • 5.2.2. By Model Type (Patient Derived Organoid (PDO) Model, Patient derived xenograft model)
    • 5.2.3. By End-Use Industry (Biopharmaceutical Companies, Government and Academic Institutes, Medical Device Companies)
    • 5.2.4. By Region
    • 5.2.5. By Company (2025)
  • 5.3. Market Map

6. North America Preclinical CRO Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Service
    • 6.2.2. By Model Type
    • 6.2.3. By End-Use Industry
    • 6.2.4. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Preclinical CRO Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Service
        • 6.3.1.2.2. By Model Type
        • 6.3.1.2.3. By End-Use Industry
    • 6.3.2. Canada Preclinical CRO Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Service
        • 6.3.2.2.2. By Model Type
        • 6.3.2.2.3. By End-Use Industry
    • 6.3.3. Mexico Preclinical CRO Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Service
        • 6.3.3.2.2. By Model Type
        • 6.3.3.2.3. By End-Use Industry

7. Europe Preclinical CRO Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Service
    • 7.2.2. By Model Type
    • 7.2.3. By End-Use Industry
    • 7.2.4. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Preclinical CRO Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Service
        • 7.3.1.2.2. By Model Type
        • 7.3.1.2.3. By End-Use Industry
    • 7.3.2. France Preclinical CRO Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Service
        • 7.3.2.2.2. By Model Type
        • 7.3.2.2.3. By End-Use Industry
    • 7.3.3. United Kingdom Preclinical CRO Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Service
        • 7.3.3.2.2. By Model Type
        • 7.3.3.2.3. By End-Use Industry
    • 7.3.4. Italy Preclinical CRO Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Service
        • 7.3.4.2.2. By Model Type
        • 7.3.4.2.3. By End-Use Industry
    • 7.3.5. Spain Preclinical CRO Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Service
        • 7.3.5.2.2. By Model Type
        • 7.3.5.2.3. By End-Use Industry

8. Asia Pacific Preclinical CRO Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Service
    • 8.2.2. By Model Type
    • 8.2.3. By End-Use Industry
    • 8.2.4. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Preclinical CRO Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Service
        • 8.3.1.2.2. By Model Type
        • 8.3.1.2.3. By End-Use Industry
    • 8.3.2. India Preclinical CRO Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Service
        • 8.3.2.2.2. By Model Type
        • 8.3.2.2.3. By End-Use Industry
    • 8.3.3. Japan Preclinical CRO Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Service
        • 8.3.3.2.2. By Model Type
        • 8.3.3.2.3. By End-Use Industry
    • 8.3.4. South Korea Preclinical CRO Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Service
        • 8.3.4.2.2. By Model Type
        • 8.3.4.2.3. By End-Use Industry
    • 8.3.5. Australia Preclinical CRO Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Service
        • 8.3.5.2.2. By Model Type
        • 8.3.5.2.3. By End-Use Industry

9. Middle East & Africa Preclinical CRO Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Service
    • 9.2.2. By Model Type
    • 9.2.3. By End-Use Industry
    • 9.2.4. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Preclinical CRO Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Service
        • 9.3.1.2.2. By Model Type
        • 9.3.1.2.3. By End-Use Industry
    • 9.3.2. UAE Preclinical CRO Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Service
        • 9.3.2.2.2. By Model Type
        • 9.3.2.2.3. By End-Use Industry
    • 9.3.3. South Africa Preclinical CRO Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Service
        • 9.3.3.2.2. By Model Type
        • 9.3.3.2.3. By End-Use Industry

10. South America Preclinical CRO Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Service
    • 10.2.2. By Model Type
    • 10.2.3. By End-Use Industry
    • 10.2.4. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Preclinical CRO Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Service
        • 10.3.1.2.2. By Model Type
        • 10.3.1.2.3. By End-Use Industry
    • 10.3.2. Colombia Preclinical CRO Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Service
        • 10.3.2.2.2. By Model Type
        • 10.3.2.2.3. By End-Use Industry
    • 10.3.3. Argentina Preclinical CRO Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Service
        • 10.3.3.2.2. By Model Type
        • 10.3.3.2.3. By End-Use Industry

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Preclinical CRO Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Eurofins Scientific SE
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. PRA Health Sciences, Inc.
  • 15.3. Medpace, Inc.
  • 15.4. Charles River Laboratories International, Inc.
  • 15.5. PPD, Inc.
  • 15.6. SGA SA
  • 15.7. Intertek Group Plc
  • 15.8. LABCORP Inc.
  • 15.9. Crown Bioscience Inc

16. Strategic Recommendations

17. About Us & Disclaimer